Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boogerd, W.
Right arrow Articles by Bruning, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boogerd, W.
Right arrow Articles by Bruning, P. F.
Neurology 2000;55:117-119
© 2000 American Academy of Neurology
Brief Communications

Response of leptomeningeal metastases from breast cancer to hormonal therapy

W. Boogerd, MD, PhD, L. D. A. Dorresteijn, MD, J. J. van der Sande, MD, PhD, G. C. de Gast, MD, PhD and P. F. Bruning, MD, PhD

From the Departments of Neuro-Oncology (Drs. Boogerd, Dorresteijn, and van der Sande) and Medical Oncology (Drs. de Gast and Bruning), Netherlands Cancer Institute, Antoni van Leeuwenhoekhuis, Amsterdam.

Address correspondence and reprint requests to Dr. W. Boogerd, Department of Neuro-Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; e-mail: irene{at}nki.nl

Intraventricular chemotherapy with radiotherapy is the standard treatment of leptomeningeal metastasis (LM) from breast cancer; this treatment increases median survival only to about 3 months and is frequently complicated by serious side effects. The authors describe two patients with LM from breast cancer who were treated with hormonal therapy, which provided a neurologic response of at least 12 months and a survival of 14+ and 19 months. Hormonal therapy can be effective and nontoxic for patients with LM from breast cancer.




This article has been cited by other articles:


Home page
 The OncologistHome page
M. C. Chamberlain
Neoplastic Meningitis
Oncologist, September 1, 2008; 13(9): 967 - 977.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Chamberlain
Neoplastic Meningitis
J. Clin. Oncol., May 20, 2005; 23(15): 3605 - 3613.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. U. Lin, J. R. Bellon, and E. P. Winer
CNS Metastases in Breast Cancer
J. Clin. Oncol., September 1, 2004; 22(17): 3608 - 3617.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Chamberlain and W. Boogerd
Response of leptomeningeal metastases from breast cancer to hormonal therapy
Neurology, February 13, 2001; 56(3): 425 - 426.
[Full Text] [PDF]